173 related articles for article (PubMed ID: 29100359)
1. The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells
Schott S; Wimberger P; Klink B; Grützmann K; Puppe J; Wauer US; Klotz DM; Schröck E; Kuhlmann JD
Oncotarget; 2017 Sep; 8(44):76935-76948. PubMed ID: 29100359
[TBL] [Abstract][Full Text] [Related]
2. ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
Invest New Drugs; 2011 Jun; 29(3):506-13. PubMed ID: 19997962
[TBL] [Abstract][Full Text] [Related]
3. Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.
Eicher C; Dewerth A; Ellerkamp V; Fuchs J; Schott S; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):121-7. PubMed ID: 23187893
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis in cervical cancer cells by the duplex drug 5-FdU-ECyd, coupling 2'-deoxy-5-fluorouridine and 3'-C-ethinylcytidine.
Schott S; Brüning A
Gynecol Oncol; 2014 Nov; 135(2):342-8. PubMed ID: 25178996
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Schott H; Schott S; Schwendener RA
Bioorg Med Chem; 2009 Oct; 17(19):6824-31. PubMed ID: 19744858
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
[TBL] [Abstract][Full Text] [Related]
7. Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.
Weinreich J; Schott S; Königsrainer I; Zieker D; Königsrainer A; Schott H
Invest New Drugs; 2011 Dec; 29(6):1294-302. PubMed ID: 20596746
[TBL] [Abstract][Full Text] [Related]
8. 3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.
Fukushima H; Abe T; Sakamoto K; Tsujimoto H; Mizuarai S; Oie S
BMC Cancer; 2014 Aug; 14():562. PubMed ID: 25087851
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro.
Weinreich J; Struller F; Sautkin I; Giuashvili S; Reymond M; Königsrainer A; Schott TC
Invest New Drugs; 2019 Jun; 37(3):415-423. PubMed ID: 30019100
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity and antileukaemic activity of new duplexes linking 3-C-ethynylcytidine and 5-fluorodeoxyuridine.
Novotny L; Rauko P; Schott H
Anticancer Res; 2010 Dec; 30(12):4891-8. PubMed ID: 21187467
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of gastric adenocarcinoma and normal cell lines against combined or conjugated antimetabolites.
Weinreich J; Struller F; Küper M; Hack A; Königsrainer A; Schott TC
Anticancer Drugs; 2013 Apr; 24(4):375-83. PubMed ID: 23358120
[TBL] [Abstract][Full Text] [Related]
12. An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.
Lui VW; Lau CP; Cheung CS; Ho K; Ng MH; Cheng SH; Hong B; Tsao SW; Tsang CM; Lei KI; Yamasaki Y; Mita A; Chan AT
Biochem Pharmacol; 2010 Jun; 79(12):1772-80. PubMed ID: 20219441
[TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
[TBL] [Abstract][Full Text] [Related]
14. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
15. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
16. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.
Howard D; James D; Garcia-Parra J; Pan-Castillo B; Worthington J; Williams N; Coombes Z; Rees SC; Lutchman-Singh K; Francis LW; Rees P; Margarit L; Conlan RS; Gonzalez D
Front Oncol; 2022; 12():1014280. PubMed ID: 36505806
[TBL] [Abstract][Full Text] [Related]
19. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Schott S; Vallet S; Tower RJ; Noor S; Tiwari S; Schem C; Busch C
Invest New Drugs; 2015 Aug; 33(4):816-26. PubMed ID: 25986684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
